Rituximab and hyaluronidase human - Biologic Drug Details

Summary for rituximab and hyaluronidase human

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for rituximab and hyaluronidase human

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody Endoglycosidase
Chemical Structure	Glycoside Hydrolases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rituximab and hyaluronidase human Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rituximab and hyaluronidase human Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2034-04-24	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2032-02-22	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2035-11-18	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2039-06-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for rituximab and hyaluronidase human Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2033-09-12	Patent claims search
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2036-03-10	Patent claims search
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2037-01-05	Patent claims search
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064		2036-12-20	Patent claims search

International Patents for rituximab and hyaluronidase human

Country	Patent Number	Estimated Expiration
Japan	2015061839
Eurasian Patent Organization	031972
Japan	5898146
Mexico	2012002861

Supplementary Protection Certificates for rituximab and hyaluronidase human

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C02475353/01	Switzerland		PRODUCT NAME: RITUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65813 28.06.2016

Market Dynamics and Financial Trajectory for Rituximab and Hyaluronidase Human

Last updated: February 24, 2026

What are the current market sizes and growth forecasts for rituximab and human hyaluronidase?

Rituximab and human hyaluronidase are key biologic agents with distinct but overlapping therapeutic areas. As of 2022, the global rituximab market was valued at approximately $7.4 billion, with a compound annual growth rate (CAGR) forecasted at 7.8% through 2027. The human hyaluronidase market, driven primarily by subcutaneous drug administration, was valued at around $400 million in 2022. It is projected to grow at a CAGR of 6.2% until 2027.

Rituximab Market Breakdown

• Key Indications: Non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and certain autoimmune conditions.
• Market Share: Rituximab accounts for roughly 75% of the monoclonal antibody (mAb) market in oncology.
• Major Players: Roche's Rituxan (Maiden form), GSK’s Riximyo, and biosimilar entrants like Sandoz’s Ruxience.

Human Hyaluronidase Market Breakdown

• Key Indications: Subcutaneous drug delivery enhancement, extravasation, and dermatological applications.
• Major Brands: Halozyme’s Hylenex, Qilu’s hyaluronidase products.
• Distribution Channels: Increasing use in outpatient and home infusion settings.

How do patent expirations and biosimilar competition influence market trajectories?

Patent expiration plays a central role in shaping the future landscape of these biologics.

Rituximab

• Patent Expiry: The primary patent for MabThera expired in Europe in 2013 and in the U.S. in 2018.
• Biosimilar Entry: Several biosimilars entered after patent expiry, including Zytux, Ruxience, and Truxima. These have reduced prices by 20–40%, pressuring originator sales.
• Pricing Trends: Biosimilars drive down prices, increasing access but squeezing profit margins for innovator firms.

Human Hyaluronidase

• Patent Status: Founded in 2002, patents have largely expired or are close to expiry.
• Market Dynamics: Competition among biosimilar and traditional enzyme sources limits pricing power.
• Regulatory Pathways: US FDA and EMA pathways promote biosimilar development, intensifying competition.

What are the regulatory and reimbursement trends affecting these drugs?

Regulatory agencies have streamlined pathways for biosimilar approval, increasing availability and competition.

• FDA: Issued the "Purple Book" listing biosimilars, with expedited review programs.
• EMA: Has approved several biosimilars for rituximab since 2017.
• Reimbursement Influences: Payors favor biosimilars to reduce costs, leading to formulary shifts away from originator biologics.

What innovations and pipeline developments could impact future revenues?

Rituximab pipeline

• Next-generation formats: Subcutaneous formulations and biosimilars are expanding accessibility.
• Combination therapies: New combinations aim to enhance efficacy.

Human Hyaluronidase pipeline

• Engineered variants: Aims for longer half-life and increased potency.
• Novel delivery systems: Combining hyaluronidase with other biologics for alternative administration routes.

How has COVID-19 affected demand and supply for these biologics?

• Supply Chain Disruptions: Manufacturing slowdowns affected availability.
• Demand Fluctuations: Decreased in non-COVID healthcare procedures initially, but recovery spurred by increased outpatient care and home infusion services.
• Pricing and Reimbursement Stability: Variations observed; some payors offered expanded access to biosimilars.

What are the key risks and opportunities?

Risks:

• Patent cliff for rituximab can accelerate biosimilar market share.
• Regulatory hurdles for new formulations or indications.
• Pricing pressures from biosimilar proliferation.

Opportunities:

• Growing prevalence of autoimmune and hematologic diseases.
• Increasing adoption of biosimilars in developed markets.
• Advancements in drug delivery technologies improving patient adherence.

Summary of investment and R&D priorities

• Companies focusing on biosimilar portfolios could benefit from market share gains.
• Innovation in delivery methods and combination therapies remains crucial.
• Regulatory environments favor biosimilar proliferation, but market penetration varies by region.

---

Key Takeaways

• The rituximab market has expanded significantly, with growth driven by biosimilar competition and expanding indications. Revenue is expected to grow at a CAGR of nearly 8% through 2027.
• Human hyaluronidase presents a smaller but steadily growing market, with growth fueled by increased use in outpatient settings and new formulations.
• Patent expirations and biosimilar entry are primary factors depressing prices and margins for originator biologics.
• Regulatory advancements streamline biosimilar approval, influencing market dynamics, especially in developed regions.
• Innovation in drug delivery and combination treatments offers pathways for growth amid intense competition.

---

FAQs

Q1: What factors most influence biosimilar adoption for rituximab?
A: Pricing strategies, regulatory approval processes, healthcare provider familiarity, and payer policies significantly impact biosimilar adoption rates.

Q2: How do biosimilars affect the profitability of originator biologics?
A: Biosimilars reduce prices by 20–40%, leading to decreased revenue for originator products but expanding patient access.

Q3: Which regions present the greatest opportunities for growth?
A: North America and Europe lead in biosimilar adoption, but emerging markets in Asia-Pacific show fast growth potential.

Q4: How does the pipeline activity for rituximab influence future revenues?
A: Next-generation formulations and combination therapies can extend lifecycle and maintain market share, but regulatory approval takes time.

Q5: Are there any significant regulatory hurdles for biosimilar approval?
A: Yes; regulators require comprehensive comparability data, with regional variations that can delay or complicate approval processes.

---

References

1. MarketWatch. (2022). Rituximab market size, share & forecast.
2. Grand View Research. (2023). Human hyaluronidase market insights.
3. U.S. Food and Drug Administration. (2022). Biosimilar approvals and guidance documents.
4. European Medicines Agency. (2022). Biosimilar guidelines and approvals.
5. IQVIA Institute. (2022). The evolving landscape of biologic and biosimilar markets.